Truex Melinda Jo sold $1.4M of LKFN (indirect holdings)

Truex Melinda Jo sold 22,500 indirectly-held shares of LAKELAND FINANCIAL CORP (LKFN) at $60.87 ($1.37M total) on 2026-10-29.

Original reporting
SEC EDGAR · Truex Melinda Jo
Published Nov 2, 2026, 7:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 7:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LKFN
Bearish
medium confidence
Mentioned
$LKFN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LKFNBearishLow
01

Why it matters

The director's complete exit may be interpreted by investors as a bearish sign, but the transaction size is modest relative to market cap.

02

Market read

Primary disclosure of a director-level insider sale; low to moderate relevance for traders.

03

What to watch

No 10b5-1 plan and zero remaining holdings may indicate personal financial reasons.

Relevance 6/10Novelty 5/10Timing: today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$LKFNBearishMedium confidence
Context

Director Melinda Jo Truex sold 22,500 shares for $1.37M, reducing her stake to zero.

Expected impact

likely modest price decline as market absorbs the insider sell.

Evidence & confidence

Director-level insider sold a sizable block at $60.87 per share; no 10b5-1 plan, indicating discretionary sale.

Market effects

Minimal impact on financial services sector; isolated insider transaction.

No broader regional effect.

Limited to LKFN shareholders.

Counterpoint

Sale could be routine liquidity need, not a negative signal.

Key entities

  • LakeLand Financial Corp

    US-listed financial services firm (ticker LKFN).

  • Melinda Jo Truex

    Director of LakeLand Financial Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LKFNMed

Raymond James reiterates Lakeland Financial stock rating after earnings beat

Raymond James maintained a Market Perform rating on Lakeland Financial (LKFN) after its Q3 earnings beat estimates, driven by higher net interest income and lower loss provisions. The company reported EPS of $1.14, above estimates, with strong loan growth and credit trends. Despite a premium valuation, InvestingPro suggests LKFN is undervalued with a PEG ratio of 0.73. The stock showed no significant movement after Q2 results, which included an earnings beat but revenue miss.

$LKFNHigh

Lakeland Financial Reports Record Third Quarter Performance with Loan Growth of 8%; Diluted Earnings per Share Increases by 11%

LAKELAND FINANCIAL CORP (LKFN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS FROM LAKELAND FINANCIAL CORPORATION FOR IMMEDIATE RELEASE Contact Lisa M. O’Neill Executive Vice President and Chief Financial Officer (574) 267-9125 lisa.oneill@lakecitybank.com Lakeland Financial Reports Record Third Quarter Performance with Loan Growth of 8%;

$LKFNMed

LAKELAND FINANCIAL CORP (LKFN): Results of Operations and Financial Condition

LAKELAND FINANCIAL CORP (LKFN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lkfn-20260727exhibit991.htm EX-99.1 Document Exhibit 99.1 NEWS FROM LAKELAND FINANCIAL CORPORATION FOR IMMEDIATE RELEASE Contact Lisa M. O’Neill Executive Vice President and Chief Financial Officer (574) 267-9125 lisa.oneill@lakecitybank.com Lakeland Financial Reports R

$MDGLMedAI 8/10

BAKER BROS. ADVISORS LP (BAKER FELIX, BAKER JULIAN) purchased $35.0M of MDGL (indirect holdings)

BAKER BROS. ADVISORS LP purchased 91,806 indirectly-held shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $381.49 ($366.99–$396.61, $35.02M total) across 5 trades over 2026-11-04 to 2026-11-06. Filed jointly with Baker Bros. Advisors (GP) LLC (Director), BAKER FELIX (Director), BAKER JULIAN (Director), 667, L.P. (Director) and Baker Brothers Life Sciences LP (Director).